Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents.
作者： Satoshi Ogawa , Yukihiro Koretsune , Masahiro Yasaka , Yoshifusa Aizawa , Hirotsugu Atarashi
关键词: Dabigatran 、 Intensive care medicine 、 Antithrombotic 、 Direct thrombin inhibitor 、 Stroke 、 Warfarin 、 Atrial fibrillation 、 Fibrinolytic agent 、 Anticoagulant 、 Medicine
摘要: Atrial fibrillation (AF) is the most common cardiac rhythm disorder and a major risk factor for stroke. For more than 60 years, warfarin has been only approved anticoagulant prevention of stroke in patients with AF. Although highly effective, it many limitations that make its use difficult. Therefore, several novel anticoagulants are under development to overcome warfarin, some these have entered phase III clinical trials. Dabigatran an oral, reversible direct thrombin inhibitor Europe other countries venous thromboembolism after elective knee hip replacement surgery. It also United States Japan systemic embolism nonvalvular In this review, mechanism action pharmacological properties new described detail, correct dabigatran practice discussed.
sci-hub.se 参考文章(20)
Rivaroxaban-once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF Study American Heart Journal. ,vol. 159, pp. 340- 347 ,(2010) , 10.1016/J.AHJ.2009.11.025
Steven V. Manoukian, Frederick Feit, Roxana Mehran, Michele D. Voeltz, Ramin Ebrahimi, Martial Hamon, George D. Dangas, A. Michael Lincoff, Harvey D. White, Jeffrey W. Moses, Spencer B. King, E. Magnus Ohman, Gregg W. Stone, Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial Journal of the American College of Cardiology. ,vol. 49, pp. 1362- 1368 ,(2007) , 10.1016/J.JACC.2007.02.027
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. ,vol. 293, pp. 690- 698 ,(2005) , 10.1001/JAMA.293.6.690
Stuart J Connolly, Michael D Ezekowitz, Salim Yusuf, Paul A Reilly, Lars Wallentin, None, Newly identified events in the RE-LY trial. The New England Journal of Medicine. ,vol. 363, pp. 1875- 1876 ,(2010) , 10.1056/NEJMC1007378
Hiroshi Inoue, Akira Fujiki, Hideki Origasa, Satoshi Ogawa, Ken Okumura, Isao Kubota, Yoshifusa Aizawa, Takeshi Yamashita, Hirotsugu Atarashi, Minoru Horie, Tohru Ohe, Yoshinori Doi, Akihiko Shimizu, Akiko Chishaki, Tetsunori Saikawa, Katsusuke Yano, Akira Kitabatake, Hideo Mitamura, Itsuo Kodama, Shiro Kamakura, Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination International Journal of Cardiology. ,vol. 137, pp. 102- 107 ,(2009) , 10.1016/J.IJCARD.2008.06.029
Yukihiro Koretsune, The incidence of ischemic stroke. Paroxysmal Af vs persistent/permanent Af. Circulation. ,vol. 73, pp. 1393- 1394 ,(2009) , 10.1253/CIRCJ.CJ-09-0440
Koichiro Ogata, Jeanne Mendell-Harary, Masaya Tachibana, Hiroshi Masumoto, Toshihiro Oguma, Masazumi Kojima, Satoshi Kunitada, Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. The Journal of Clinical Pharmacology. ,vol. 50, pp. 743- 753 ,(2010) , 10.1177/0091270009351883
M. A. CROWTHER, T. E. WARKENTIN, Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. Journal of Thrombosis and Haemostasis. ,vol. 7, pp. 107- 110 ,(2009) , 10.1111/J.1538-7836.2009.03429.X
Jörg Hauptmann, Jörg Stürzebecher, Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thrombosis Research. ,vol. 93, pp. 203- 241 ,(1999) , 10.1016/S0049-3848(98)00192-3